Srinivasa Prahalada, Ph.D.
Global Consultant - Safety Assessment
Prahalada holds a Ph.D in Comparative Pathology and MS in Anatomy from the University of California and a Bachelor’s degree in Veterinary Medicine from the University of Agricultural Sciences, Bangalore. Prior to joining Syngene in 2016, he was working with Merck and Company (MSD) for over 28 years during which period he moved up the ranks to become the Head of Pathology in Safety Assessment. He was responsible for preclinical development of many compounds which resulted in successful registration globally. He was also the Head of Pathology at the Regional Primate Center, University of California, Davis for 3 years. Dr Prahalada has an impressive list of scientific publications in peer-reviewed journals in the areas of developmental pathology, anatomic pathology, toxicology and reproductive endocrinology.
Mahesh Bhalgat, Ph.D
Chief Operating Officer
Mahesh holds a Ph.D. in Medicinal Chemistry from the University of Utah, the USA, and a bachelor’s degree in Pharmacy from the University of Mumbai. He has over 25 years of experience in both biotechnology and biologics. Mahesh has worked in different facets of R&D which include analytical development, technology transfer, regulatory sciences and quality. During his career, he has been associated with companies such as Celera Genomics, Molecular Probes, Monsanto and Amgen. Prior to joining Syngene, he was the Chief Operating Officer at Shantha Biotechnics, a Sanofi company, where his responsibilities included operations and long-term strategic planning and development. As Chief Operating Officer and a member of the Executive Committee at Syngene, Mahesh is responsible for operational efficiency, safety, quality and compliance.
Kenneth Barr, Ph.D
Sr. Vice President – Discovery Services
Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology and has pursued his Postdoctoral study in Natural product synthesis from the University of Texas. He has over two decades of experience in the areas of drug discovery for both small and large molecules and has been associated with organisations like Merck, Amplyx Pharmaceuticals Inc. and Sunesis. Prior to joining Syngene, Kenneth was the Head of R&D Strategic Global Operations at FORMA Therapeutics, where he was responsible for driving research effectiveness through optimisation of internal and external R&D research efforts, providing alliance management for key CRO relationships.
Chief Human Resources Officer
Vinita holds a post-graduate degree in Management from Barkatullah University, India and School of Industrial and Labor Relations, Cornell University (USA), Vinita has over two decades of experience in the HR domain. Her prior experience includes working with HCL Technologies and Harman International Inc. She was the CHRO for India and Senior Director for Global Mobility at Harman. Prior to joining Syngene, Vinita was the Senior Vice President and Chief Human Resource Officer at Sasken Technologies Limited leading HR for multiple sites across geographies which included India, US, China, Finland, Japan and the UK. As a member of the Executive Committee and CHRO, Vinita spearheads various innovation led initiatives to strengthen the HR function.
Chief Quality Officer
Alok holds an M. Tech in Chemical Technology (Food Technology) from Harcourt Butler Technological Institute. He comes with more than 25 years of experience spread across Manufacturing Operations, Quality Assurance, Sustainability/EHS, Production and Supplier Technical Assurance across varied industries. Over the years, Alok has worked with leading corporates including Godrej Foods and Beverages Ltd., PepsiCo Foods India and Reckitt Benckiser. In his most recent assignment as Head of Operations Excellence, EHS and Sustainability at Dr. Reddy's Laboratories, he put in place an integrated Quality Management System to monitor the quality of external suppliers and vendors. As Syngene's CQO, Alok leads the Quality and Compliance function and will be in-charge of initiatives to further strengthen our track record in quality and compliance
Anjan Chakrabarti, Ph.D
Head – Discovery Chemistry
Anjan holds a Ph.D. in Organic Chemistry from the Indian Institute of Chemical Technology, Hyderabad and has completed post-doctoral work at GlaxoSmithKline (GSK), Collegeville, PA, USA which was funded by NIH. Anjan has completed his Executive Program in Management from the University of California at Berkeley’s Haas School of Business. He has over 20 year of global experience in drug discovery and been associated with organisations like Affymax and Albany Molecular Research Inc., (AMRI). Anjan has experience in several therapeutic areas – hematology, oncology, antibacterial, anti-HIV, CNS & anti-inflammatory. He has more than 25 patents & publications to his credit. Prior to joining Syngene, Anjan is a Senior Director and Head of AMRI’s Singapore Research operation and lead AMRI’s drug discovery research efforts in Asia with cross-functional teams in India and Singapore. At Syngene he is responsible for leading the Discovery Chemistry Group of over 800 scientists engaged in drug discovery. The team consists of medicinal chemists, analytical and CADD scientists engaged in drug discovery projects in multiple therapeutic areas. He is also involved in defining the business development and marketing strategy for discovery chemistry and integrated drug discovery.
Chief Commercial Officer
Ashu holds a BA (Economics) degree from the University of Delhi, India as well as a Post Graduate Diploma in International Marketing from the Delhi School of Economics. He completed his MBA from IMT Ghaziabad, India and has over 20 years experience in the global biopharmaceuticals industry which includes Sales and Account Management leadership across consulting & outsourcing services in Research & Development. Ashu is based out of New Jersey and has global responsibility for Syngene’s commercial activities, including leading the business development team as well as developing new capabilities in marketing, brand building, digital & account management. As a member of the Executive Committee, he plays an important role in driving strategy as it relates to Commercial activities. Prior to joining Syngene, Ashu was at IQVIA (formerly QuintilesIMS), Infosys and Accenture.
Purushottam Singnurkar, Ph.D.
Head- Formulations Development
Purushottam holds a Ph.D from the Birla Institute of Technology & Science, Pilani and done Masters degree in Pharmacy from the University of Pune . He is a pharmaceutical development leader with 20 years of experience in product development including new drug delivery systems, analytical, pharmacokinetic studies and CMC development. He has developed over 90 novel and generic formulations which have been commercialized and has several patents to his credit. Prior to joining Syngene in 2012, he worked with Sandoz Development Centre as a Group Head – Formulation.
Chetan Tamhankar, Ph.D.
Head - Clinical Development and Stability Studies
Chetan holds a Ph.D in Bio-pharmaceuticals and a Masters in Pharmacology from Mumbai University. He has more than 19 years of experience in life-sciences business spanning across CRO and healthcare sectors. He played active role in healthcare startups and has held senior management roles in other leading CROs. Prior to joining Syngene in 2016, Chetan has been associated with SIRO Clinpharm.
Gregory Bisacchi, Ph.D
Global Head - Integrated Drug Discovery
Gregory holds a Ph.D. in Organic Chemistry from the University of California, Los Angeles and did his postdoctoral work in Organic Synthesis at Stanford University. He has over 20 years of experience in the area of chemistry and has held key positions at various global organizations including AstraZeneca and Bristol-Myers Squibb. At BMS, Greg led projects in the development of the anti- hepatitis B virus nucleoside analog entecavir, launched in 2004 under the trade name Baraclude. He has authored or co- authored more than 40 peer reviewed chemistry and medicinal chemistry journals, articles and book chapters, and is inventor on 37 patents. Prior to joining Syngene in 2015, Greg worked with AstraZeneca as Associate Director.